Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Cardiovasc Hematol Agents Med Chem ; 22(3): 390-398, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38275031

RESUMO

BACKGROUND: Studies have shown the combination treatment effectiveness of using rosuvastatin and ezetimibe in patients with chronic coronary artery disease. Our study aim to evaluate the effectiveness of dyslipidemia treatment with the combination of rosuvastatin and ezetimibe 10mg in patients with chronic coronary artery disease compared with 20 mg rosuvastatin. OBJECTIVES: To evaluate the effectiveness of dyslipidemia treatment with the target of LDL-c < 1.4 mmol/L between combination therapy with rosuvastatin 10 mg and ezetimibe 10 mg in patients with chronic coronary artery disease compared with monotherapy increasing the dose of rosuvastatin 20 mg in Vietnam. METHODS: A randomized controlled clinical trial, single-blind, parallel-group with a 1:1 randomized ratio in 103 outpatients with chronic coronary syndromes treated with rosuvastatin 10mg daily. Group A received the combination therapy with rosuvastatin 10 mg plus ezetimibe 10 mg daily, and group B received rosuvastatin 20 mg daily. The primary outcome was to assess the efficacy of low-density lipoprotein - cholesterol (LDL-c) control between rosuvastatin 10 mg plus ezetimibe 10 mg versus rosuvastatin 20 mg after 4 weeks and 8 weeks. RESULTS: After 8 weeks of intervention, the proportion of archived treatment target patients with LDL-c < 1.4 mmol/L in groups A and B was 69.2% and 44.2%, respectively (Risk ratio (RR) = 1.57, p < 0.01), 50% LDL reduction was 27.9% and 55.8%, respectively (RR = 2.00, p < 0.01), and archived both targets were 51.9% and 25.6% (RR = 2.03, p < 0.01). CONCLUSION: Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg). Both medication therapies were safe in patients, and the increased dose of monotherapy showed more side effects than the combination therapy.


Assuntos
Quimioterapia Combinada , Dislipidemias , Ezetimiba , Rosuvastatina Cálcica , Humanos , Rosuvastatina Cálcica/uso terapêutico , Rosuvastatina Cálcica/administração & dosagem , Ezetimiba/uso terapêutico , Ezetimiba/administração & dosagem , Masculino , Pessoa de Meia-Idade , Feminino , Método Simples-Cego , Dislipidemias/tratamento farmacológico , Dislipidemias/sangue , Idoso , Anticolesterolemiantes/uso terapêutico , Anticolesterolemiantes/administração & dosagem , LDL-Colesterol/sangue , Doença Crônica , Doença da Artéria Coronariana/tratamento farmacológico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Resultado do Tratamento
2.
Glob Cardiol Sci Pract ; 2023(4): e202326, 2023 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-38623555

RESUMO

Background: Mitral regurgitation (MR) is a common heart valve disease, causing many serious complications in several organ systems, especially the cardiovascular system. The 2D speckle tracking echocardiography (STE) is a new technique for detecting potential cardiac dysfunction when only tissue function abnormalities are present. The study aimed to assess left ventricular (LV) systolic function early by STE in patients with primary MR through global LV deformity along the global longitudinal strain (GLS). Methods: An analytical cross-sectional study was performed on 46 patients with moderate to severe primary MR as recommended by the American Society of Echocardiography (ASE) 2017. Results: The prevalence of patients with GLS reduction with ejection fraction (EF) >60%, New York Heart Association (NYHA) I, and left ventricular internal diameter systolic (LVIDs) <40 mm was 38.1%, 35.7%, and 39.5%, respectively. 100% of patients with EF<60% and LVIDs ≥40 mm had reduced GLS (<16%). The GLS index strongly correlates with the NYHA classification, degree of MR, EF, and echocardiographic parameters. Conclusion: GLS index gives a significant sign in the early detection of cardiac function abnormalities before symptoms or other echocardiographic parameters in patients with MR.

3.
Mycologia ; 98(3): 374-83, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17040066

RESUMO

In this study we analyzed the spatial structure of ectomycorrhizal fungi present in the soils as resistant propagules (e.g. spores or sclerotia) in a mixed-conifer forest in the Sierra Nevada, California. Soils were collected under old-growth Abies spp. stands across approximately 1 km and bioassayed with seedlings of hosts that establish best in stronger light (Pinus jeffreyi) or that are shade-tolerant (Abies concolor). Ectomycorrhizal fungi colonizing the roots were characterized with molecular techniques (ITSRFLP and DNA sequence analysis). Wilcoxina, five Rhizopogon species and Cenococcum were the most frequent of 17 detected species. No spatial structure was detected in the resistant propagule community as a whole, but P. jeffreyi seedlings had higher species richness and associated with seven Rhizopogon species that were not detected on A. concolor seedlings. We drew two conclusions from comparisons between this study and a prior study of the ectomycorrhizal community on mature trees in the same forest: (i) the resistant propagule community was considerably simpler and more homogeneous than the active resident community across the forest and (ii) Cenococcum and Wilcoxina species are abundant in both communities.


Assuntos
Ascomicetos/classificação , Basidiomycota/classificação , Micorrizas , Plântula/microbiologia , Árvores , Abies/crescimento & desenvolvimento , Abies/microbiologia , Ascomicetos/genética , Basidiomycota/genética , California , DNA Espaçador Ribossômico/análise , Ecossistema , Dados de Sequência Molecular , Pinus/crescimento & desenvolvimento , Raízes de Plantas/microbiologia , Polimorfismo de Fragmento de Restrição , Plântula/crescimento & desenvolvimento , Análise de Sequência de DNA , Microbiologia do Solo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA